Overview
- Pfizer and BioNTech reported topline Phase 3 results showing at least a four-fold rise in neutralizing antibodies in adults 65 and older and in high-risk adults 18 to 64 for the LP.8.1-adapted, 30‑µg monovalent Comirnaty 2025–2026 formula.
- The companies said the safety profile matched prior studies and no new safety concerns were identified.
- Coverage characterizes the immunogenicity data as supportive of U.S. authorization, though regulators have not issued a decision.
- Guggenheim maintained a Buy rating on Pfizer with a $33 price target in a September 5 report, citing continued confidence in the outlook.
- Pfizer highlights broader momentum with oncology and hematology updates and continues a $4.5 billion cost‑savings program and a July licensing deal with 3SBio to support R&D and expand market reach.